{"id":53867,"date":"2015-02-13T09:53:47","date_gmt":"2015-02-13T09:53:47","guid":{"rendered":"http:\/\/mostafa.openonline.co.uk\/?guid=6acea212145c58718ccd6f817a293d1b"},"modified":"2015-02-13T09:53:47","modified_gmt":"2015-02-13T09:53:47","slug":"press-release-hormone-replacement-therapy-hrt-and-the-risk-of-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/mostafa.openonline.co.uk\/?p=53867","title":{"rendered":"Press release: Hormone replacement therapy (HRT) and the risk of ovarian cancer"},"content":{"rendered":"
\n

Dr Sarah Branch, Deputy Director of MHRA\u2019s Vigilance and Risk Management of Medicines (VRMM) Division said: <\/p>\n

\n

Our advice has always been that the lowest effective dose of HRT<\/abbr> should be used for the shortest possible time.<\/p>\n

We will evaluate the findings of this study and its implications for shorter-term use and update product information as necessary.<\/p>\n

The decision to start, continue or stop HRT<\/abbr> should be made jointly by a woman and her doctor, based on the best advice available and her own personal circumstances, including her age, her need for treatment and her medical risk factors.<\/p>\n

Women on HRT<\/abbr> should have regular health check-ups and their need to continue treatment should be re-assessed at least annually.<\/p>\n

Any woman on HRT<\/abbr> who has any questions should speak to her doctor who is best placed to advise.<\/p>\n<\/blockquote>\n

\n
\n

Media enquiries<\/h3>\n
\n

\nPress office<\/span>
4 T
\n
\n151 Buckingham Palace Road
\n
\nVictoria<\/span>
London<\/span>
SW1W 9SZ<\/span>\n<\/p>\n

\n

\n Email<\/span>
\n press.office@mhra.gsi.gov.uk<\/a>\n <\/p>\n

\n During office hours:<\/span>
\n 020 3080 7651\n <\/p>\n

\n Out of office hours:<\/span>
\n 07770 446 189\n <\/p>\n<\/p><\/div>\n

Office hours are Monday to Friday, 9am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at twitter.com\/mhrapress<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MHRA statement in response to the study in The Lancet on the use of HRT.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/53867"}],"collection":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53867"}],"version-history":[{"count":0,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/53867\/revisions"}],"wp:attachment":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}